SHORT MINI-FUTURE - MODERNA | Market Closed - Deutsche Boerse AG 13:53:33 2024-06-14 EDT | ||
| 5.68 EUR | +13.60% |
|
| Current month | +6.57% | ||
| 1 month | -15.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 5.68 | +13.60% |
| 24-06-13 | 5 | +7.30% |
| 24-06-12 | 4.66 | -2.71% |
| 24-06-11 | 4.79 | -0.62% |
| 24-06-10 | 4.82 | +7.59% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 01:53 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU2VMZ |
| ISIN | DE000VU2VMZ2 |
| Date issued | 2023-01-31 |
| Strike | 199.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.19 € |
|---|---|
| Lowest since issue | 1.63 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- Certificat
